Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Real-Time Price · USD
9.95
-0.62 (-5.87%)
At close: Nov 20, 2026, 4:00 PM EST
10.07
+0.12 (1.21%)
After-hours: Nov 20, 2026, 7:54 PM EST
Summit Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
265
Market Cap
7.96B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 705.00K | -1.10M | -61.03% |
| Dec 31, 2021 | 1.81M | 949.00K | 110.35% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Madrigal Pharmaceuticals | 1.43B |
| Corcept Therapeutics | 963.65M |
| TG Therapeutics | 897.76M |
| Protagonist Therapeutics | 551.69M |
| Twist Bioscience | 459.43M |
| Rhythm Pharmaceuticals | 280.75M |
| Cytokinetics | 113.29M |
| Praxis Precision Medicines | 7.46M |
SMMT News
- 1 day ago - Summit Therapeutics to Host Corporate Update and Operational Progress Call on November 30, 2026 - Business Wire
- 2 days ago - Summit Therapeutics price target lowered to $11 from $13 at Leerink - TheFly
- 3 days ago - Bernstein downgrades Summit Therapeutics to Underperform, lowers target to $8.30 - TheFly
- 3 days ago - Summit Therapeutics downgraded to Underperform from Market Perform at Bernstein - TheFly
- 3 days ago - Summit Therapeutics initiates new global Phase 3 trial of ivonescimab - TheFly
- 3 days ago - Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase III HARMONi-10 Study in Unresectable Stage III Non-Small Cell Lung Cancer - Business Wire
- 3 days ago - Summit Therapeutics' stock tumbles again as FDA recommends new trial for lung-cancer drug - Market Watch
- 5 days ago - Summit Therapeutics falls -14.4% - TheFly